All In Biotech

Drug Trial Radar · NCT03777657

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 997 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

997

Actual

Start

Dec 13, 2018

Primary completion

Feb 28, 2023

Study completion Aug 27, 2024

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Dec 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Conditions

  • Gastric, or Gastroesophageal Junction Adenocarcinoma

Interventions

  • TislelizumabDrug

    200 mg intravenously (IV) on Day 1 of each 21-day cycle

  • PlaceboDrug

    Placebo to match tislelizumab IV on Day 1 of each 21-day cycle

  • CisplatinDrug

    80 mg/m² IV on Day 1 of each 21-day cycle

  • OxaliplatinDrug

    130 mg/m² IV on Day 1 of each 21-day cycle

  • CapecitabineDrug

    1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) of each 21-day cycle

  • 5-FluorouracilDrug

    800 mg/m²/day IV using continuous infusion on Days 1 to 5 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival in PD-L1 Positive ParticipantsTime frame: From randomization up to the primary analysis data cut-off date of 8 October 2021; Median (range) time on follow-up was 11.8 (0.1 - 33.4) months.
  2. Overall Survival in the Intent-to-Treat (ITT) Analysis SetTime frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

Locations

149 sites in 13 countries. Site status is shown where the registry gives one.

  • University of California Davis Health System

    Sacramento, California

  • Southeastern Regional Medical Center

    Newnan, Georgia

  • Ohio State University Hospital

    Columbus, Ohio

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Reading Hospital

    West Reading, Pennsylvania

  • Tennessee Oncology, Pllc Nashville

    Nashville, Tennessee

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital

    Hefei, Anhui, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Beijing Chao Yang Hospital

    Beijing, Beijing Municipality, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Chinese Pla General Hospital

    Beijing, Beijing Municipality, China

  • Beijing Luhe Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Daping Hospital, Third Military Medical University

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Foshan First Peoples Hospital

    Foshan, Guangdong, China

  • Sun Yat Sen University Cancer Center

    Guangzhou, Guangdong, China

  • Guangdong Provincial Peoples Hospital

    Guangzhou, Guangdong, China

  • Shenzhen Peoples Hospital

    Shenzhen, Guangdong, China

  • Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • Hainan General Hospital

    Haikou, Hainan, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Henan Provincial Peoples Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • Nantong Tumor Hospital Branch South

    Nantong, Jiangsu, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

Showing 40 of 149 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.